Clinical trial · Interventional
EGFR-targeted Therapy for Gastric Cancer
Anti-EGFR Antibody (GC-1118) in Combination With Weekly Paclitaxel as a Second-line Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas With Amplifications
NCT04077255CI-TRIAL-00062394unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of the Stomach | Gastric Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anti-EGFR antibody in combination with weekly paclitaxel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- anti-EGFR
- description
- Participants will receive GC-1118 in combination with weekly paclitaxel.
- interventionNames
- Drug: Anti-EGFR antibody in combination with weekly paclitaxel
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- Response rate will be assessed at 8 weeks.
- description
- Response rate will be assessed using CT/MRI according to RECIST v1.1.
Secondary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- From date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, will be assessed up to 1 year.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key inclusion criteria 1. Histologically-proven gastric and gastroesophageal junction adenocarcinoma 2. Refractory to first-line chemotherapy for metastatic disease 3. Presence of at least 1 measurable lesion according to RECIST version 1.1 4. EGFR gene amplification or strong (3+ or 2+) EGFR immunostaining Key exclusion criteria 1.Prior exposure to taxane or EGFR-targeted therapy
References
Publications (0)
Data not yet available
No reference posted for this study.